icariin and its derivative (H Lee Moffitt Cancer Center and Research Institute)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Nameicariin and its derivative (H Lee Moffitt Cancer Center and Research Institute)
Drug Alias NameicariinICA/ICT (H Lee Moffitt Cancer Center and Research Institute)ICTICA
ClassificationSmall moleculesNatural product/Extract
Mechanisms of ActionS100 calcium binding protein A9 modulatorsMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33S100 calcium binding protein A9
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesH Lee Moffitt Cancer Center & Research Institute
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A